TransThera Sciences (Nanjing), Inc.
藥捷安康（南京）科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2617)

(1) POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 18 JUNE 2026; (2) CHANGE OF THE INDEPENDENT NON-EXECUTIVE DIRECTOR AND COMPOSITION OF BOARD COMMITTEES; (3) CANCELLATION OF THE SUPERVISORY COMMITTEE; AND (4) AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND ITS APPENDICES

The Board is pleased to announce that all proposed resolutions were duly passed by the Shareholders by way of poll at the AGM held on 18 June 2026.

References are made to the notice of the annual general meeting (the "**Notice**") and the circular (the "**Circular**") of TransThera Sciences (Nanjing), Inc. (the "**Company**") both dated 26 May 2026. Unless stated otherwise, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

The Board is pleased to announce that all proposed resolutions as set out in the Notice were duly passed by the Shareholders at the AGM by way of poll.

As at the date of the AGM, the total number of issued Shares of the Company was 407,918,633 Shares, of which 312,687,673 Shares were H Shares and 95,230,960 Shares were Unlisted Shares. All Shares entitled the holders to attend the AGM and vote on the resolutions proposed at the AGM.

No Shareholder was required under the Listing Rules to abstain from voting on the proposed resolutions at the AGM. There were no Shares entitling the Shareholders to attend the AGM but abstain from voting in favour of the proposed resolutions at the AGM under Rule 13.40 of the Listing Rules. None of the Shareholders have stated his, her or its intention in the Circular to vote against or to abstain from voting on the resolutions at the AGM.

Tricor Investor Services Limited, the H share registrar of the Company acted as the scrutineer for the vote-taking at the AGM.

All Directors attended the AGM.

The poll results in respect of all proposed resolutions at the AGM are as follows:

ORDINARY RESOLUTIONS		Number of votes (%)		
		FOR	AGAINST	ABSTAIN
1.	To consider and approve the 2025 report of the board of directors (the "**Board**") of the Company.	313,250,389 (99.879%)	5,000 (0.001%)	375,000 (0.120%)
2.	To consider and approve the 2025 report of the supervisory committee ("**Supervisory Committee**") of the Company.	324,496,233 (99.883%)	5,000 (0.002%)	375,000 (0.115%)
3.	To consider and approve the 2025 audited consolidated financial statements of the Company.	325,327,643 (99.883%)	5,000 (0.002%)	375,000 (0.115%)
4.	To consider and approve the 2025 Annual Report.	324,995,079 (99.883%)	5,000 (0.002%)	375,000 (0.115%)
5.	To consider and approve the uncovered losses amounting to over one-third of the total paid-up share capital of the Company.	325,327,643 (99.883%)	5,000 (0.002%)	375,000 (0.115%)
6.	To consider and approve the 2025 profit distribution plan of the Company.	325,327,643 (99.883%)	5,000 (0.002%)	375,000 (0.115%)
7.	To consider and approve the re-appointment of Ernst & Young as auditor of the Company for 2026, and to authorize the Board to fix its remuneration.	325,327,643 (99.883%)	5,000 (0.002%)	375,000 (0.115%)
8.	To consider and approve the remuneration plan for directors ("**Director(s)**") of the Company for 2026.	325,327,643 (99.883%)	5,000 (0.002%)	375,000 (0.115%)
9.	To consider and approve the remuneration plan for supervisors ("**Supervisor(s)**") of the Company for 2026.	325,327,643 (99.883%)	5,000 (0.002%)	375,000 (0.115%)
10.	To consider and approve the election of Director of the second session of the Board.			
	(1) To elect Mr. Feng Weibo as an independent non-executive Director of the second session of the Board.	314,169,188 (99.875%)	17,000 (0.005%)	375,000 (0.120%)

SPECIAL RESOLUTIONS		Number of votes (%)		
		FOR	AGAINST	ABSTAIN
11.	To grant a general mandate to the Directors to allot, issue and deal with (including sale or transfer of any treasury shares) additional Shares (details of this resolution were set out in the notice of AGM dated 26 May 2026).	307,252,325 (94.334%)	16,417,500 (5.041%)	2,037,818 (0.625%)
12.	To grant a general mandate to the Directors to repurchase H Shares (details of this resolution were set out in the notice of AGM dated 26 May 2026).	323,664,825 (99.373%)	5,000 (0.002%)	2,037,818 (0.625%)
13.	To extend the general mandate granted under resolution no. 11 by adding the Shares repurchased pursuant to the general mandate granted by resolution no. 12.	307,252,376 (94.334%)	16,417,449 (5.041%)	2,037,818 (0.625%)
14.	To consider and approve the proposed cancellation of the Supervisory Committee, the proposed amendments to business scope and proposed amendments to the Articles of Association and its appendices.	323,159,903 (99.883%)	5,000 (0.002%)	375,000 (0.115%)

As a majority of the votes were cast in favour of each of the resolutions numbered 1 to 10, these resolutions were duly passed as ordinary resolutions.

As more than two-thirds of the votes were cast in favour of the resolutions numbered 11 to 14, these resolutions were duly passed as special resolutions.

CHANGE OF THE INDEPENDENT NON-EXECUTIVE DIRECTOR AND COMPOSITION OF BOARD COMMITTEES

Reference is made to (i) the announcement of the Company dated 31 March 2026 in relation to, among other things, the resignation of independent non-executive Director and the proposed appointment of independent non-executive Director, and (ii) the Circular.

As approved at the AGM, Mr. Feng Weibo ("**Mr. Feng**") has been appointed as an independent non-executive Director of the second session of the Board, with effect from 18 June 2026 until the expiry of the term of the second session of the Board. Meanwhile, Mr. Feng has been appointed as the chairman of the remuneration and appraisal committee of the Board (the "**Remuneration and Appraisal Committee**"), and a member of the audit committee of the Board (the "**Audit Committee**") and the nomination committee of the Board (the "**Nomination Committee**"). Biographical details of Mr. Feng and other information required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules are set out in the Circular. As at the date of this announcement, there has been no change to such information. The Board would like to extend its warm welcome to Mr. Feng for joining the Board.

Ms. Zheng Zhelan ("**Ms. Zheng**") no longer serves as an independent non-executive Director of the Company upon the conclusion of the AGM. Ms. Zheng has ceased to be the chairperson of the Remuneration and Appraisal Committee, and a member of the Audit Committee and the Nomination Committee. The Board would like to express its appreciation to Ms. Zheng for her contributions to the Company during her term of office. Ms. Zheng has confirmed that she has no disagreement with the Board and that there are no other matters in relation to her resignation that need to be brought to the attention of the Shareholders or the Stock Exchange.

CANCELLATION OF THE SUPERVISORY COMMITTEE

The Company hereby announces that the Company has dissolved the Supervisory Committee, effective from 18 June 2026. The powers and functions of the Supervisory Committee shall be exercised by the Audit Committee. The provisions involving the Supervisory Committee and supervisors in various rules and regulations of the Company shall no longer apply. Each of the Supervisors has confirmed that he/she has no disagreement with the Company and the Board in any respect, and there is no other matter that needs to be brought to the attention of the Shareholders or the Stock Exchange. The Company would like to take this opportunity to express its sincere gratitude to each of the Supervisors for their contributions to the Company during their tenures as the Supervisors.

AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND ITS APPENDICES

As a special resolution in relation to the proposed amendments to the Articles of Association and its appendices has been duly approved by the Shareholders at the AGM, the amended Articles of Association and its appendices shall take effect upon conclusion of the AGM. The full text of the amended Articles of Association is available on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.transthera.com).

By Order of the Board
TransThera Sciences (Nanjing), Inc.
藥捷安康(南京)科技股份有限公司
Dr. Frank Wu
Chairman and Chief Executive Officer

Hong Kong, 18 June 2026

As at the date of this announcement, the Board comprises Dr. Frank Wu and Mr. Wu Di as executive Directors; Ms. Jia Zhongxin as a non-executive Director; and Mr. Li Shu Pai, Ms. Chui Hoi Yam and Mr. Feng Weib as independent non-executive Directors.